Approval · Notice of Compliance 17094 · 2015
IPG-RANITIDINE: Notice of Compliance 17094
Issued July 16, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17094
- Date
- July 16, 2015
- Company
- International Pharmaceutical Generics LtdOttawa, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Histamine h2 receptor antagonist
- Canadian reference product
- ZANTAC (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IPG-RANITIDINE | 02443708 | Marketed |
| IPG-RANITIDINE | 02443716 | Marketed |
Medicinal ingredients
- RANITIDINE HCL 150 MG per TAB
- RANITIDINE HCL 300 MG per TAB